Grade: Pharmaceutical Grade

Factory Location: Xiamen, China

Main Sales Markets: North America

Sample Provided: no

Payment Terms: L/C

 

Product name	Vildagliptin
CAS No.	274901-16-5
Molecular Formula	C17H25N3O2
Molecular Weight	303.404
Quality Standard	99% up by HPLC
Appearance	White or whitish solid powder

 

COA of Vildagliptin

 

ITEMS	SPECIFICATION	RESULT
Appearance	White or whitish solid powder	White solid powder
Identity	High-performance liquid chromatograph HPLC: The retention time of test sample major peak complies to reference standard	Almost the same
	IR Infrared spectrometry: The IR spectrum of test sample should comply to reference standard	Almost the same
Melting point	148.0 。C - 152.0。C	148.6.0。C-149.1。C
Loss on drying	≤ 1.0%	0.36%
Residual on ignition	≤ 0.1%	0.04%
Related substance	Any single impurity ≤ 0.1% Total impurities ≤ 1.0%	Conforms 0.65%
Heavy metals	≤ 20 ppm	< 10 ppm
Assay	99.0% - 102.0%	99.19%
Conclusion	The sample complies with the above specification

 

Usage

 

Vildagliptin is a selective, competitive and reversible DPP24 inhibitor. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like polypeptide 1 (GLP-1) are important hormones to maintain glucose concentration in the body, and both have incretin effects. The insulin-stimulating effect of GIP in patients with type 2 diabetes is impaired, and only GLP-1 can play the role of insulin-stimulating hormone secretion. GLP-1 also inhibits glucagon secretion and suppresses gastric emptying to increase satiety (suppression of appetite). DPP24 binds to proteins and exists in many tissues, such as kidney, liver, brush border of small intestinal membrane, pancreatic duct, lymphocytes, endothelial cells, and it can rapidly degrade GLP-1 by hydrolyzing the N-terminal 2 alanine of GLP-1. inactivated. This product inhibits the activity of this enzyme by combining with DPP24 to form a DPP24 complex. It increases the concentration of GLP-1 and promotes the production of insulin by islet β cells, while reducing the concentration of glucagon, thereby reducing blood sugar. and had no significant effect on body weight.

 

Vildagliptin can reduce fasting and postprandial blood glucose levels, postprandial glucagon secretion and improve B cell function, providing a new option for the treatment of type 2 diabetes patients. Safety and effectiveness of this medicine in combination with other medicines.